ClinicalTrials.gg
Not yet recruitingNCT07281027COMBAT-NORSEUpdated Aug 19, 2026

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

A Phase 3 interventional study of Anakinra and Tocilizumab in New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus and Febrile Infection-Related Epilepsy Syndrome (FIRES), sponsored by Yale University. Not yet recruiting at 33 sites in 7 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Yale University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.

Planned enrollment
5th of 30
438 · median 35
Started
2026
with 1 other
Phase 3
8 of 41
2 open now
Primary completion
2030-03
later than 10 of 12 live
Registered
39th of 41
by date
Lead sponsor
2 of 41
Yale University

Among the 41 studies in Status Epilepticus with a site in United States, this one is the 5th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 10 of the 12 other live ones, and was the 39th registered.

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

Browse Status Epilepticus studies →

Open to participants now

13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Status Epilepticus with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus). NORSE causes continuous seizures in previously healthy children and adults and does not respond to standard treatments. It often leads to long-term disability or death.

Doctors currently use anakinra and tocilizumab as second-line treatments when first-line therapies fail, but there is no clear evidence showing which drug works better or when it should be given. This study aims to answer those questions.

The study will enroll patients across 33 hospitals in the United States, Canada, Europe, and Asia.

It includes two groups:

  1. Randomized Cohort Patients will be randomly assigned to receive either anakinra or tocilizumab within the first 7 days of their illness. Only patients whose doctors were already planning to use one of these medications as part of standard care will be eligible for randomization. Researchers will monitor their recovery and compare outcomes between the two treatments.
  2. Observational Cohort Patients who cannot be randomized-usually because they were diagnosed too late-will still be followed to study how the timing of treatment affects recovery.

Participants will:

  • Receive one of the two medications (depending on their group assignment).
  • Take part in follow-up assessments over the course of one year, including medical evaluations and surveys. Some participants may be followed annually beyond one year.
  • Optionally participate in a 60-minute interview to share their or their caregiver's experience with NORSE.
03

Conditions studied

  • New Onset Refractory Status Epilepticus
  • New-Onset Refractory Status Epilepticus
  • Febrile Infection-Related Epilepsy Syndrome (FIRES)

Browse trials for

Keywords

  • refractory status epilepticus
  • NORSE
  • FIRES
  • anakinra
  • tocilizumab
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 2 and older.
  • In their usual state of health prior to their onset of SE.
  • Presenting with NORSE as defined in the consensus criteria:

    1. SE (failed 2 appropriately used anti-seizure medications) in a patient without active epilepsy or other pre-existing relevant neurological disorder and without an acute or active structural, toxic, or metabolic cause found in the first 72 hours.
    2. Includes patients with any RSE, not just super-refractory SE.
    3. Includes patients who ultimately are discovered to have a known etiology (infectious, , genetic, etc.), as well as those who remain cryptogenic.

      • Additional Inclusion Criteria for the Randomized Arm:
  • Anakinra and/or tocilizumab are being planned or considered as part of standard clinical care.
  • The onset of SE was in the prior 7 days at the time of enrollment.

Exclusion criteria

Exclusion Criteria:

  • Any acute or active systemic medical illness such as cancer, renal failure, hepatic failure, poorly controlled diabetes, etc., in the opinion of the investigators. If this is unclear, the study PI Dr. Hirsch will determine if this criterion is met.

Additional Exclusion Criteria for the Randomized Control Cohort:

  • to either anakinra or tocilizumab as listed in the prescribing information:

    1. Known to E. Coli-derived proteins, anakinra, tocilizumab, or any component of the products
    2. Active serious infection at the time of initiation
    3. Concomitant use of TNF blocking agents; \< 2000; count \< 100,000 per mm³; or or AST > 1.5 X the
    4. Elevated risk of GI perforation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
438 participants (estimated)

Study arms

  • Active comparator
    Randomized Controlled Trial (RCT) Cohort

    A randomized controlled cohort (RCT) of anakinra vs. tocilizumab (targeted immunotherapies) started up to and including 7 days after the onset of status epilepticus (SE)

    Drug: Anakinra · Drug: Tocilizumab

  • Other
    Observational Cohort

    An observational cohort enrolling patients with acute cryptogenic NORSE who cannot be randomized or who are identified too late to be randomized by the end of day 7 .

    Other: Standard medical treatment

Interventions

  • DrugInterleukin 1 Receptor Antagonist ProteinStudies of Interleukin 1 Receptor Antagonist ProteinInterleukin 1 Receptor Antagonist Protein pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SOC will be followed , Suggested Dose: 10 mg/kg/day IV, divided into 4 daily doses (q6h) Maximum dose: 400 mg/day

  • SOC will be followed, Suggested Dose: If \<30 kg: 12 mg/kg IV once every 2 weeks If ≥30 kg: 8 mg/kg IV once every 2 weeks Maximum dose: 800 mg per dose

  • OtherStandard medical treatment

    For patients who could not be randomized by day 7, standard clinical care will be followed and patients will be followed prospectively and observationally.

06

What researchers measure

Primary outcomes

  1. Glasgow Outcome Scale - Extended (GOS-E)

    The Glasgow Outcome Scale - Extended (GOS-E) is an 8-point scale used to measure global functional outcome. Participants are scored into one of the 8 categories: 1. Death, 2. Vegetative State, 3. Lower Severe Disability, 4. Upper Severe Disability, 5. Lower Moderate Disability, 6. Upper Moderate Disability, 7. Lower Good Recovery, 8. Upper Good Recovery.

    Time frame: 12 months

Secondary outcomes

  1. Time to resolution of status epilepticus (SE)

    Time (days) until discontinuation of anesthetic drips for 24h for the treatment of SE with no return of SE on EEG

    Time frame: 24 hours off anesthetic drips

  2. Hospital length of stay

    Mean number of days during hospitalization from admission to discharge

    Time frame: 12 months

  3. Mortality

    Mortality, number of participants

    Time frame: up to 12 months

  4. Number of serious adverse events attributed to anakinra or tocilizumab

    Number of serious adverse events attributed to anakinra or tocilizumab

    Time frame: From hospitalization to 1 month after stopping treatment, up to 12 months

  5. Number of participants Post-NORSE epilepsy

    Number of participants with any unprovoked seizures after hospital discharge

    Time frame: 12 months

  6. Number of participants with Treatment success

    Combined measure of lack of need for another immunomodulator after the study drug was begun, plus good outcome at 1 year (GOS-E of 5-8) (Yes/No)

    Time frame: 12 months

07

Study locations

33 sites
08

References and documents

Individual participant data

Plan to share: Yes — Making the Full Data Package available to enable other researchers (including PCORI) to use it to re-analyze the data or for independent (i.e., novel) research analyses.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Mar 2030, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 15, 2025
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 31, 2030
CompletionEst.
Sep 30, 2030
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07281027
Lead sponsor
Yale University
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Lawrence Hirsch (Professor of Neurology, Yale University) — Principal investigator
First posted
Dec 15, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 31, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Aug 19, 2026

Study contacts

Camalene Chrysostoum
Contact
camalene.chrysostoum@yale.edu
2037375851
Tara McPartland
Contact
tara.mcpartland@yale.edu
2037375851
Lawrence Hirsch, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion